SEARCH:   Advanced

Blood, 1 March 2008, Vol. 111, No. 5, pp. 2581-2588. Prepublished online as a Blood First Edition Paper on January 2, 2008; DOI 10.1182/blood-2007-08-107482. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-08-107482v1 111/5/2581    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Deenik, W. Articles by Cornelissen, J. J. PubMed PubMed Citation Articles by Deenik, W. Articles by Cornelissen, J. J. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia Wendy Deenik1, Bronno van der Holt1, Gregor E. G. Verhoef2, Willem M. Smit3, Marie J. Kersten4, Hanneke C. Kluin-Nelemans5, Leo F. Verdonck6, Augustin Ferrant7, Anton V. M. B. Schattenberg8, Jeroen J. W. M. Janssen9, Pieter Sonneveld1, Marinus van Marwijk Kooy10, Shulamit Wittebol11, Roelof Willemze12, Pierre W. Wijermans13, Petra H. M. Westveer1, H. Berna Beverloo1, Peter Valk1, Bob Löwenberg1, Gert J. Ossenkoppele9, and Jan J. Cornelissen1 1 Erasmus University Medical Center, Rotterdam, The Netherlands; 2 University Hospital Gasthuisberg, Leuven, Belgium; 3 Medical Spectrum Twente, Enschede, The Netherlands; 4 Academic Medical Center, Amsterdam, The Netherlands; 5 University Medical Center Groningen, Groningen, The Netherlands; 6 University Medical Center Utrecht, Utrecht, The Netherlands; 7 University Hospital St-Luc, Brussels, Belgium; 8 Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands; 9 Vrije Universiteit Medical Center, Amsterdam, The Netherlands; 10 Isala Clinic-Sophia, Zwolle, The Netherlands; and 11 Meander Medical Center, Amersfoort, The Netherlands; 12 Leiden University Medical Center, Leiden, The Netherlands; and 13 Haga Hospital, The Hague, The Netherlands The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase chronic myeloid leukemia (CML). Patients received 2 cycles of intravenous cytarabine (200 mg/m2 or 1000 mg/m2 days 1-7) in conjunction with imatinib (200 mg, 400 mg, 600 mg, or 800 mg), according to predefined, successive dose levels. All dose levels proved feasible. Seven dose-limiting toxicities (DLTs) were observed in 302 cycles of chemotherapy, which were caused by streptococcal bacteremia in 5 cases. Intermediate-dose cytarabine (1000 mg/m2) prolonged time to neutrophil recovery and platelet recovery compared with a standard dose (200 mg/m2). High-dose imatinib (600 mg or 800 mg) extended the time to platelet recovery compared with a standard dose (400 mg). More infectious complications common toxicity criteria (CTC) grade 3 or 4 were observed after intermediate-dose cytarabine compared with a standard-dose of cytarabine. Early response data after combination therapy included a complete cytogenetic response in 48% and a major molecular response in 30% of patients, which increased to 46% major molecular responses at 1 year, including 13% complete molecular responses. We conclude that combination therapy of escalating dosages of imatinib and cytarabine is feasible. This study was registered at www.kankerbestrijding.nl as no. CKTO-2001-03. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020